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Abstract 
Non-invasive cardiac stress imaging plays a central role in the assessment of 
patients with known or suspected coronary artery disease. The current 
guidelines suggest estimation of the myocardial ischaemic burden as a 
criterion for revascularisation on prognostic grounds despite the lack of 
standardised reporting of the magnitude of ischaemia on various 
non-invasive imaging methods. Future studies should aim to accurately 
describe the relationship between myocardial ischaemic burden as assessed 
by cardiovascular magnetic resonance imaging and mortality.  
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Core tip: Further studies should aim to accurately describe the relationship 
between myocardial ischaemic burden as assessed by stress cardiovascular 
magnetic resonance and mortality.  
 
INTRODUCTION 
Non-invasive cardiac stress imaging plays a central role in guiding the 
treatment of patients with known or suspected coronary artery disease 
(CAD). Stress testing techniques performed include stress echocardiography, 
single photon emission computed tomography (SPECT) myocardial perfusion 
imaging and more recently cardiovascular magnetic resonance imaging 
(CMR). All functional tests support diagnosis, risk stratification and 
subsequent management decisions[1] and thus allow myocardial ischaemia to 
play a crucial role in the management of patients with CAD[2]. As the 
availability and use of CMR increases, it is increasingly emerging as the gold 
standard method of safe, radiation-free perfusion imaging providing 
functional assessment and tissue characterisation.  
In this editorial, we focus on a recent article by Heitner et al[3] published in 
JAMA Cardiology as we feel it is an important study adding credence to the 
growing role of pharmacological stress CMR in the assessment of patients 
with known or suspected CAD . We will also provide our perspective for the 
future direction of stress CMR.  
 
STUDY ANALYSIS 
Heitner et al[3] provided real-world data for 9151 patients referred for 
evaluation of myocardial ischaemia with stress CMR across 7 participating 
centres followed for a total of 48000 patient-years. Their analysis 
demonstrated a strong association of abnormal CMR results with all-cause 
mortality over long-term follow-up up to 10 years with a hazard ratio of 1.8 
between the patients who had abnormal scans and those that did not. This 
hazard ratio remained significant in all 8 patient subpopulations 
(presence/absence of history of CAD, normal/abnormal left ventricular 
ejection fraction (LVEF), presence/absence of typical chest pain, 
presence/absence of Late Gadolinium Enhancement). The multivariate 
analysis also showed that addition of stress CMR in two different models 
significantly increased the χ2 from 581.8 to 687.4 (P < 0.001) and from 620.7 to 
721.1 (P < 0.001) respectively, indicating that the addition of stress CMR in the 
model significantly predicts mortality over and above the other variables 
(including age, sex, diabetes, hypertension, hyperlipidaemia, smoking status, 
history of CAD or Myocardial Infarction, body mass index, family history of 
CAD and LVEF).  
Whilst this was not a randomised control trial, it crucially provides 
real-world data and demonstrated for the first time that stress CMR is 
significantly associated with mortality. The major strengths of the study lie in 
the large number of patients included and the high number of outcomes over 
long-term follow up. It is important to consider however, that there were 
certain limitations. The cause of death is not known in the study and future 
studies will have to investigate if stress CMR is able to predict specific 
cardiovascular events rather than all-cause mortality. Nevertheless, as 
discussed by the authors, all-cause mortality is an objective, unbiased and 
clinically relevant hard end point. The authors also acknowledged that they 
had not been able to determine if patients were revascularised after the stress 
CMR. They reasonably anticipated that revascularisation would occur more 
commonly in patients with abnormal stress CMR and that revascularisation 
would improve prognosis and not increase mortality. Another important 
limitation is that the study CMRs did not assess the extent of ischaemic 
burden but instead categorised ischaemia into “negative” or “positive” even if 
just one segment showed abnormal perfusion. Although full quantified 
perfusion[4] is not yet part of routine practice, visual semi-quantitative 
methods have been described[5] and might have further improved the 
association with mortality. Furthermore, information about patient 
revascularisation in combination with myocardial ischaemic burden (MIB) 
might had allowed estimation of a threshold for MIB, similarly to the way it 
was estimated in the SPECT studies originally [6], providing valuable 
information regarding the threshold of ischaemic burden as assessed with 
stress CMR .  
Hachamovitch et al[6] for the first time in 2003 successfully estimated the 
10% MIB threshold with SPECT above which revascularisation offers a 
survival benefit over medical therapy, using propensity match scoring of 
observational data. In 2011, the same group used SPECT to demonstrate in a 
slightly larger observational series that patients with significant ischaemia but 
without extensive scar were likely to benefit from revascularisation in contrast 
to patients with minimal ischaemia[7]. The 10% threshold for myocardial 
ischaemia based on SPECT has correlated with perfusion defect in 2/16 
segments on CMR[8] and has been incorporated in the ESC 2018 guidelines as 
a criterion for revascularisation on prognostic grounds and in the 
ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 guidelines as a 
high-risk indicator[1,9]. Despite the significance of ischaemia in decision 
making, there is a lack of standardized reporting of the magnitude of 
ischaemia on non-invasive testing, which contributes to the variability in 
translating the severity of ischaemia across stress imaging modalities[8]. Given 
the high diagnostic and prognostic yield of pharmacological stress CMR with 
regards to CAD, it will be valuable for future studies to attempt to delineate 
the relationship between MIB and prognosis. Nonetheless, Heitner et al[3] 
should be highly commended for contributing to the medical literature; a very 
well undertaken and described study including a significant number of 
patients and an extended follow up, supporting the prognostically beneficial 
use of CMR perfusion in the routine evaluation of patients with suspected 
coronary artery disease. 
 
FUTURE DIRECTIONS 
Over the last few years, adenosine stress CMR has been established as a 
highly accurate non-invasive and radiation-free method for the diagnosis and 
prognosis of CAD. The initial CE-MARC study demonstrated that stress CMR 
was superior to SPECT regarding the diagnostic accuracy for CAD[10]. It has 
also been shown that compared with stress echocardiography, stress CMR 
was the strongest independent predictor of significant CAD among patients 
with intermediate probability of CAD presenting to emergency 
department[11]. The 5-year follow up data from CE-MARC study 
demonstrated that stress CMR was the only significant predictor of MACE in 
addition to major cardiovascular risk factors, angiographic findings or the 
effect of initial treatment[12]. Even though stress CMR is not universally, easily 
available currently, the increasing number of studies demonstrating its cost 
effectiveness over other non-invasive imaging modalities indicate that it will 
become more widely available in the near future[13-15]. In addition to accurate 
assessment of ischaemia, stress CMR offers accurate localisation of ischaemic 
segments and the extent of myocardial scar, which have prognostic 
implications[16]. It has been shown that ischaemia in ≥ 1.5 myocardial 
segments (in a 16 segment model) is significantly associated with poor 
prognosis as is the presence of myocardial scar, albeit to a lesser degree[17].  
Two potential drawbacks of stress CMR perfusion include the visual 
assessment of perfusion defects as well as the incomplete myocardial 
coverage. The continuous development of quantified myocardial perfusion 
reserve aims to reduce the inherent interpreter-bias of visual assessment and 
to increase the diagnostic ability in the presence of triple-vessel disease. 
Comparison of quantitative myocardial perfusion reserve with qualitative 
assessment of stress CMR has demonstrated that quantitative assessment 
differentiates significantly better the MIB particularly in the context of 
triple-vessel disease[18]. More recently, it was also shown that quantitative 
assessment of MIB was superior to visual assessment with respect to 
prognosis[4]. The ongoing development of whole-heart perfusion aims to 
address the limited, non-contiguous coverage of 2D stress CMR and 
ultimately provide a non-invasive, non-ionizing radiation method for 
accurate measurement of MIB. It has been demonstrated that whole-heart 
perfusion CMR has high diagnostic accuracy for the detection of significant 
CAD as defined by Fractional Flow Reserve, while estimation of MIB by 
whole-heart perfusion has very good correlation with SPECT[19,20]. 
Comparison of whole-heart perfusion with high-resolution 2D perfusion has 
shown that there is strong correlation between the two techniques for the 
estimation of MIB however, there is still uncertainty around the clinically 
relevant threshold of 10%[21].  
In summary, non-invasive accurate assessment of myocardial ischaemic 
burden is a clinical necessity with significant implications for prognosis and 
clinical decision making. In the near future, further development of stress 
CMR perfusion techniques may reveal that quantified, whole-heart perfusion 
is the most accurate non-invasive method for the diagnosis and prognosis of 
CAD.  
 CONCLUSION 
Heitner et al[3] showed for the first time that stress CMR is significantly 
associated with worse mortality in a large study of real-world data. This is an 
important study that confirms the prognostic significance of stress CMR in 
terms of mortality in the real world. The study is a valuable addition to the 
growing volume of data that supports the central role of CMR in the 
diagnosis and stratification of CAD in routine clinical practice. However, as 
information about MIB as assessed by stress CMR was not available, future 
studies could aim to describe accurately the relationship between MIB, 
revascularisation and mortality. 
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